Neurotherapeutic Cephalosporin Sulfoxide and Sulfone-Containing Compositions

Abstract

The treatment of neurological disorders using cefazolin compositions and pharmaceutical compositions including oral dosage forms that include cefazolin compositions are described.

1 - 21 . (canceled) 
     
     
         22 . A method for treating a patient suffering from a disorder selected from a neurological disorder, a behavioral disorder, or a cognitive disorder, comprising administering a pharmaceutical formulation to the patient, wherein the pharmaceutical formulation comprises a compound in an effective amount for treating a neurological disease, a behavioral disorder, or a cognitive disorder; and wherein the compound is selected from the group consisting of Δ 2 -cefazolin sulfoxide, Δ 3 -cefazolin sulfoxide, Δ 2 -cefazolin sulfone, Δ 3 -cefazolin sulfone, Δ 2 -ceftriaxone sulfoxide, Δ 3 -ceftriaxone sulfoxide, Δ 2 -ceftriaxone sulfone, Δ 3 -ceftriaxone sulfone, combinations thereof, pharmaceutically acceptable salts thereof, and active esters thereof. 
     
     
         23 . The method of  claim 22 , wherein the compound is selected from the group consisting of Δ 2 -cefazolin sulfoxide, Δ 3 -cefazolin sulfoxide, combinations thereof, pharmaceutically acceptable salts thereof, and active esters thereof. 
     
     
         24 . The method of  claim 22 , wherein the compound has the formula: 
       
         
           
           
               
               
           
         
         wherein n is 1 or 2; R is hydrogen, an active ester forming group, or a pharmaceutically acceptable cation; and B is 
       
       
         
           
           
               
               
           
         
       
     
     
         25 . The method of  claim 24 , wherein R is selected from the group consisting of indanyl, acyloxyalkyl, and alkyloxycarbonyloxyalkyl. 
     
     
         26 . The method of  claim 24 , wherein R is selected from the group consisting of 1-indanyl, acetoxyalk-1-yl, isopropoxycarbonyloxyalk-1-yl, and pivaloyloxyalk-1-yl. 
     
     
         27 . The method of  claim 22 , wherein the compound has the formula: 
       
         
           
           
               
               
           
         
       
     
     
         28 . The method of  claim 27 , wherein R is selected from the group consisting of indanyl, acyloxyalkyl, and alkyloxycarbonyloxyalkyl. 
     
     
         29 . The method of  claim 27 , wherein R is selected from the group consisting of 1-indanyl, acetoxyalk-1-yl, isopropoxycarbonyloxyalk-1-yl, and pivaloyloxyalk-1-yl. 
     
     
         30 . The method of  claim 22 , wherein the compound has the formula: 
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of indanyl, acyloxyalkyl, and alkyloxycarbonyloxyalkyl. 
       
     
     
         31 . The method of  claim 22 , wherein the compound has the formula: 
       
         
           
           
               
               
           
         
         wherein R is selected from the group consisting of 1-indanyl, acetoxyalk-1-yl, isopropoxycarbonyloxyalk-1-yl, and pivaloyloxyalk-1-yl. 
       
     
     
         32 . The method of  claim 22 , wherein the pharmaceutical formulation is administered orally. 
     
     
         33 . The method of  claim 22 , wherein the pharmaceutical formulation is administered parenterally. 
     
     
         34 . The method of  claim 22 , wherein the disorder is a neurological disorder. 
     
     
         35 . The method of  claim 22 , wherein the disorder is a behavioral disorder. 
     
     
         36 . The method of  claim 22 , wherein the disorder is a cognitive disorder.